ScholarLens Back to search
2023•Journal of Nuclear MedicineOpen access

Sequential and Combination Therapies of223RaCl2and Prostate-Specific Membrane Antigen Radioligand Therapy

Hossein Jadvar

Open full text 2 citations

Abstract

There have been unprecedented strides in theranostics, facilitating the bidirectional “see and treat” concept in precision oncology. The momentous VISION trial inaugurated prostate-specific membrane antigen (PSMA)–targeted, β-emitter 177Lu–labeled radioligand therapy (RLT) as a viable

Open-access reader

About this research paper

What this paper is about

There have been unprecedented strides in theranostics, facilitating the bidirectional “see and treat” concept in precision oncology. The momentous VISION trial inaugurated prostate-specific membrane antigen (PSMA)–targeted, β-emitter 177Lu–labeled radioligand therapy (RLT) as a viable

Why it matters

OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

There have been unprecedented strides in theranostics, facilitating the bidirectional “see and treat” concept in precision oncology. The momentous VISION trial inaugurated prostate-specific membrane antigen (PSMA)–targeted, β-emitter 177Lu–labeled radioligand therapy (RLT) as a viable

Key concepts: Radioligand, Glutamate carboxypeptidase II, Prostate cancer, Prostate-specific antigen, Medicine, Oncology, Internal medicine, Cancer research

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Sequential and Combination Therapies of223RaCl2and Prostate-Specific Membrane Antigen Radioligand Therapy — Research Paper | ScholarLens